Andrew Albert, MD
Gastroenterology · Chicago, ILNPI 1659413656
Payments from drug & device makers
Across 46 payments — averaging $434.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Celltrion USA Inc.$13K
- Takeda Pharmaceuticals U.S.A., Inc.$3K
- Exact Sciences$3K
- AbbVie$167
- Johnson & Johnson$161
- Madrigal Pharmaceuticals$144
- plus $383 from 11 others
What the payments were for
- Consulting fees$4,59623%
- Speaking & faculty fees$12,75164%
- Travel & lodging$1,4677%
- Food & beverage$1,0855%
- Education$670%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Celltrion USA Inc. | 14 | $13,213 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $3,399 |
| Exact Sciences | 1 | $2,500 |
| AbbVie(2 entities) | 9 | $167 |
| Johnson & Johnson | 5 | $161 |
| Madrigal Pharmaceuticals | 2 | $144 |
| E.r. Squibb & Sons, L.L.C. | 1 | $125 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $37 |
| Ardelyx, Inc. | 1 | $34 |
| Cook Medical LLC | 1 | $33 |
| Covidien LP | 1 | $31 |
| Pfizer | 1 | $29 |
| QOL Medical, LLC | 1 | $27 |
| Fresenius Kabi USA, LLC | 1 | $24 |
| Lilly USA, LLC | 1 | $22 |
| Boston Scientific | 1 | $18 |
| Organon | 1 | $5 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ZYMFENTRA$12,967
- Entyvio$3,390
- Cologuard Collection Kit$2,500
- REZDIFFRA$123
How this compares
$19,967 in reported general payments places this provider in the 80th percentile of 787 gastroenterology providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Omeprazole | 30 | $504 |
| Pantoprazole Sodium | 43 | $383 |
| Ursodiol | 12 | $333 |
| Lactulose | 15 | $176 |
| Famotidine | 21 | $158 |
Paid to pharmacies, not to this prescriber.
Other gastroenterology in Chicago
- David RubinChicago$3.6M
- Stephen HanauerChicago$2.9M
- Parambir DulaiChicago$2.2M
- Ikuo HiranoChicago$1.8M
- Steven FlammChicago$1.6M
- Darren BrennerChicago$1.1M
- Russell CohenChicago$985K
- Mary RinellaChicago$938K
- Emanuelle BellaguardaChicago$868K
- Saurabh KapurChicago$867K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.